Evidence mapPaperPMID 42226278Full record

ArticleStem cell research & therapy2026

Development of a novel GAK solution for efficient hypothermic preservation of NK cell viability and anti-tumor function.

Xin Wang, Xiaolong Liu, Guangyuan Wu, Hailong Wang, Kuo Yu, Yang Liu, Hongrui Xu, Xin Sun, Zhongyao An, Linlin Zhao and 3 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xin Wang *NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Xiaolong Liu *NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Guangyuan Wu *NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Hailong WangNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Kuo YuNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Yang LiuNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Hongrui XuNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Xin SunNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Zhongyao AnNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Linlin ZhaoDepartment of Blood Transfusion, First Affiliated Hospital, Harbin Medical University, Harbin, China.
Ce ShiNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Mingli HuangNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China.
Zhenkun WangNHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China. zhenkunwang@hrbmu.edu.cn.

Funding

Collaborative Innovation Projects of Heilongjiang Province LJGXCG2023-003the National Natural Science Foundation of China 82101929the Outstanding Youth Funding of the First Affiliated Hospital of Harbin Medical University 2021J02
6 · The paper itself

Abstract

backgroundNatural killer cells exhibit significant potential within current immunotherapeutic modalities. Hypothermic preservation is a critical step for the clinical transportation and temporary storage of NK cell products. However, during this process, both cell viability and function significantly decrease. The core damage mechanisms remain unclear, and effective, specialized preservation protocols are currently lacking. This study aimed to elucidate the primary modes of cell death and maintain NK cell potency during hypothermic preservation.

methodsThis study first evaluated the effects of different intravenous fluids and temperatures on NK cell preservation efficiency. Subsequently, various cell death inhibitors, molecular biomarker assays, and electron microscopy techniques were utilized to systematically elucidate the modes of cell death. Based on these findings, we optimized the best-performing fluids by replacing sodium lactate with glucose to enhance energy supply, adding the antioxidant α-tocopherol to mitigate oxidative stress, and elevating the potassium ion concentration (to 22.5 mM) to suppress excessive nutrient uptake and associated oxidative damage. These optimizations were incorporated into a new formulation designated as the GAK solution. The preservation efficacy was comprehensively assessed through in vitro cell viability and cytotoxicity assays, as well as an in vivo leukemia xenograft model.

resultsStorage at 4 °C was much better than at 25 °C. Among the tested intravenous fluids, lactated Ringer's demonstrated the highest efficacy in preserving NK cell viability and function. NK cells undergo complex death pathways during hypothermic preservation, specifically ferroptosis, pyroptosis, and necroptosis. Our optimized GAK effectively mitigates energy depletion and oxidative stress, significantly maintaining the viability and potent cytotoxic capacity of NK cells against various tumor cells after hypothermic storage. In vivo experiments further demonstrated that NK cells preserved in the GAK solution maintained significant antitumor activity, which contributed to prolonged survival in tumor-bearing mice.

conclusionsThis study revealed multiple death mechanisms of NK cells during hypothermia and successfully developed a well-defined and highly efficient GAK solution. The GAK solution presents a new approach to the hypothermic preservation of NK cells, facilitating the efficient and convenient transport of NK cell products, which has significant practical implications for the accelerated clinical adoption of cellular immunotherapy.

Indexed as

CryopreservationKiller Cells, Naturalalpha-TocopherolAnimalsCell SurvivalHumansMicePotassiumalpha-TocopherolPotassiumAntioxidantGlucose uptakeHigh potassiumHypothermic preservationNatural killer cellsα-tocopherol

Identifiers

PMID42226278
PMCPMC13440123

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.